PL2034997T3 - Kompozycje przeciwbakteryjne - Google Patents

Kompozycje przeciwbakteryjne

Info

Publication number
PL2034997T3
PL2034997T3 PL07733310T PL07733310T PL2034997T3 PL 2034997 T3 PL2034997 T3 PL 2034997T3 PL 07733310 T PL07733310 T PL 07733310T PL 07733310 T PL07733310 T PL 07733310T PL 2034997 T3 PL2034997 T3 PL 2034997T3
Authority
PL
Poland
Prior art keywords
antibacterial compositions
antibacterial
compositions
Prior art date
Application number
PL07733310T
Other languages
English (en)
Polish (pl)
Inventor
David John Haydon
Lloyd George Czaplewski
Nicholas John Palmer
Dale Robert Mitchell
John Frederick Atherall
Christopher Richard Steele
Tamara Ladduwahetty
Original Assignee
Biota Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Europe Ltd filed Critical Biota Europe Ltd
Publication of PL2034997T3 publication Critical patent/PL2034997T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL07733310T 2006-06-22 2007-06-21 Kompozycje przeciwbakteryjne PL2034997T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612428.3A GB0612428D0 (en) 2006-06-22 2006-06-22 Antibacterial agents
EP20070733310 EP2034997B1 (en) 2006-06-22 2007-06-21 Antibacterial compositions
PCT/GB2007/002314 WO2007148093A1 (en) 2006-06-22 2007-06-21 Antibacterial compositions

Publications (1)

Publication Number Publication Date
PL2034997T3 true PL2034997T3 (pl) 2013-04-30

Family

ID=36803739

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07733310T PL2034997T3 (pl) 2006-06-22 2007-06-21 Kompozycje przeciwbakteryjne

Country Status (21)

Country Link
US (2) US7977340B2 (OSRAM)
EP (1) EP2034997B1 (OSRAM)
JP (1) JP5309021B2 (OSRAM)
KR (1) KR101443795B1 (OSRAM)
CN (1) CN101472585B (OSRAM)
AU (1) AU2007262791B2 (OSRAM)
BR (1) BRPI0713501A2 (OSRAM)
CA (1) CA2655403C (OSRAM)
DK (1) DK2034997T3 (OSRAM)
EA (1) EA019748B1 (OSRAM)
ES (1) ES2403005T3 (OSRAM)
GB (1) GB0612428D0 (OSRAM)
IL (1) IL195687A (OSRAM)
MX (1) MX2008015706A (OSRAM)
MY (1) MY148682A (OSRAM)
NZ (1) NZ574313A (OSRAM)
PL (1) PL2034997T3 (OSRAM)
PT (1) PT2034997E (OSRAM)
SG (1) SG172676A1 (OSRAM)
WO (1) WO2007148093A1 (OSRAM)
ZA (1) ZA200900240B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
JP2010511682A (ja) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ 抗菌性の多環系尿素化合物
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2277870A1 (de) * 2009-06-24 2011-01-26 Bayer CropScience AG Substituierte Benzoxa(thia)zole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
SG191927A1 (en) 2011-01-14 2013-08-30 Vertex Pharma Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
AU2012205415B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Pyrimidine gyrase and topoisomerase IV inhibitors
CA2824401A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
MX355561B (es) 2011-01-14 2018-04-23 Spero Trinem Inc Proceso para hacer inhibidores de girasa y topoisomerasa iv.
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
KR101941420B1 (ko) 2011-06-20 2019-01-23 스페로 트리넴, 인코포레이티드 자이라제 및 토포이소머라제 억제제의 인산에스테르
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013142712A1 (en) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
TWI595002B (zh) 2012-07-18 2017-08-11 思沛羅三南公司 （Ｒ）－２－（５－（２－（３－乙基脲基）－６－氟－７－（四氫呋喃－２－基）－１Ｈ－苯并［ｄ］咪唑－５－基）嘧啶－２－基）丙烷－２－基磷酸二氫鹽之固體形式及其鹽
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US20160194279A1 (en) * 2012-12-09 2016-07-07 Council Of Scientific & Industrial Research One pot process for the conversion of aroyl chlorides to acyl thioureas
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
JP2017504662A (ja) 2014-02-03 2017-02-09 スペロ ジャイレース インク ポリミキシンを含む抗菌剤の組合せ
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2016087417A1 (de) * 2014-12-02 2016-06-09 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
US20180000793A1 (en) * 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
US10513528B2 (en) 2016-02-25 2019-12-24 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
EP3604281A4 (en) 2017-03-24 2020-08-19 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
WO2018183917A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CN114127056A (zh) 2019-07-17 2022-03-01 萨米特(牛津)有限公司 制备ridinilazole及其晶型的方法
US20230247994A1 (en) 2020-07-02 2023-08-10 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
CN116444376B (zh) * 2023-04-19 2024-01-26 德兴市德邦化工有限公司 一种3,5-二氯硝基苯的生产工艺
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
CN119350937B (zh) * 2024-10-30 2025-08-12 广东豪之盛新材料有限公司 一种双组份气雾喷漆及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
US4028374A (en) 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
SK12712002A3 (sk) * 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
JP3886897B2 (ja) * 2000-06-21 2007-02-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
DE60131015T2 (de) * 2000-12-15 2008-07-10 Vertex Pharmaceuticals Inc., Cambridge Bakterielle gyrase-hemmer und deren verwendung
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1790640A4 (en) * 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Also Published As

Publication number Publication date
SG172676A1 (en) 2011-07-28
KR20090029817A (ko) 2009-03-23
MY148682A (en) 2013-05-31
DK2034997T3 (da) 2013-02-11
NZ574313A (en) 2011-10-28
AU2007262791B2 (en) 2012-11-08
US20110263590A1 (en) 2011-10-27
CA2655403C (en) 2014-02-04
CN101472585A (zh) 2009-07-01
KR101443795B1 (ko) 2014-10-21
IL195687A0 (en) 2009-09-01
EA200900047A1 (ru) 2009-06-30
EA019748B1 (ru) 2014-06-30
EP2034997A1 (en) 2009-03-18
EP2034997B1 (en) 2012-10-17
US8389516B2 (en) 2013-03-05
ES2403005T3 (es) 2013-05-13
CN101472585B (zh) 2013-12-04
JP2009541289A (ja) 2009-11-26
US7977340B2 (en) 2011-07-12
ZA200900240B (en) 2009-12-30
CA2655403A1 (en) 2007-12-27
IL195687A (en) 2013-12-31
PT2034997E (pt) 2013-01-24
AU2007262791A1 (en) 2007-12-27
MX2008015706A (es) 2009-03-31
US20090197877A1 (en) 2009-08-06
WO2007148093A1 (en) 2007-12-27
GB0612428D0 (en) 2006-08-02
BRPI0713501A2 (pt) 2012-03-13
JP5309021B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
IL195687A0 (en) Antibacterial compositions
GB0623838D0 (en) Novel compositions
GB0624340D0 (en) Antimicrobial composition
EP2182811A4 (en) ANTIMICROBIAL COMPOSITIONS
EP2059126A4 (en) ANTIMICROBIAL COMPOSITION CONTAINING ISOTHIAZOLIN-3-ONE
GB0607085D0 (en) Novel compositions
GB0625069D0 (en) Compositions
GB0620279D0 (en) Compositions
GB0618657D0 (en) Compositions
GB0607605D0 (en) Composition
ZA200809821B (en) Novel antibacterial compounds
GB0620918D0 (en) Compositions
GB0601899D0 (en) Compositions
GB0917779D0 (en) Novel compositions
GB0611033D0 (en) Compositions
GB0723589D0 (en) Antibacterial compositions
GB0524239D0 (en) Antibacterial compositions
GB0600411D0 (en) Compositions
GB0621950D0 (en) Compositions
GB0624424D0 (en) Compositions
GB0620204D0 (en) Compositions
GB0610477D0 (en) Compositions
GB0622456D0 (en) Compositions
GB0621751D0 (en) Compositions
GB0622092D0 (en) Compositions